Amgen investors have high expectations for Amgen's Business Review Day, scheduled for April 21. With Medicare's coverage decision on...

First, there were just words. Then there was a maiden dividend , the first of regular payouts to shareholders . Now there's a white pape...

Actelion's CEO Jean-Paul Clozel clashed entertainingly with one of the Swiss biotech's biggest (and newest) shareholders during the ...

Even though the New Year has come and gone, analysts are still making their predictions about what 2011 will bring for the pharma and biotec...

The biggest deal of the week wasn't a chart-topper just because of its size. It was also likely the tip of a much larger iceberg. We...

It was with amusement that we noted Elan CEO Kelly Martin hold up our little old blog as part of his defense of Elan's "18% solutio...

With all due respect to our FOTF brethren , DOTW may take the occasional vacation from writing intros to our columns, but we somehow manage ...

In honor of the 2010 FIFA World Cup, IN VIVO Blog is channelling its inner Andres Cantor . Come on, there’s a little bit of the Argentinian-...

Biotechnology Value Fund is making moves. Public records show the high-profile public investor recently grabbed a 6.6% share of the stagger...

Far from achieving "clarity" in its Alcon takeover by bidding for the minority shareholders' 23% stake as well as buying up Ne...

Friday's announcement that bits of rubber and other detritus were found in vials of five different drugs manufactured at Genzyme's ...

Does the approval of Vanda's iloperidone (now given the 'just for you, crazy sportsfan!' name of Fanapt )--deemed Not Approvabl...

Titanic, Meet Iceberg. Iceberg, Meet Titanic. Just what did these two men say to each other on Monday at the press conference announcing the...